Bristol-Myers Squibb Company

EU Legislative Interests

28th Regime for Innovative Companies European Innovation Act Public Procurement Act European Research Area Act European Biotech Act I European Biotech Act II Omnibus on taxation Interest and Royalties Directive (Council Directive 2003/49/EC) Tax Merger Directive (Council Directive 2009/133/EC) Parent-Subsidiary Directive (Council Directive 2011/96/EU) Anti-Tax Avoidance Directive (Council Directive (EU) 2016/1164) Tax Dispute Resolution Mechanisms Directive (Council Directive 2017/1852). Framework for Income Taxation (BEFIT) Communication on better regulation Update of antitrust procedural rules Anti-corruption strategy Review of the anti-fraud architecture Evaluation of the customs enforcement of intellectual property rights The AI act The Apply AI Strategy Data governance: EHDS Cloud and AI Development Act Quantum Act Gender equality strategy 2026-2030 UWWTD PFAS EU economic governance framework Corporate sustainability reporting and due diligence Patent package Screening of foreign investments System of own resources of the European Union Multiannual financial framework Trade and Economic Security Advanced Therapy Medicinal Products Capital Markets Union

Communication Activities

BMS is a member of the All.Can initiative https://www.all-can.org/about-us/ Blood and Beyond https://bloodandbeyond.com/ Cardiomyopathies Matter cardiomyopathiesmatter.org BMS Linked-In Profile (Bristol Myers Squibb EU Policy) BMS EU policy website (www.eupolicy.bms.com).

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

European Federation of Pharmaceutical Industries and Associations (EFPIA), EFPIA Oncology Platform, EFPIA Cardiovascular Health Platform, EFPIA Alzheimer's Platform, DigitalEurope, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Friends of Europe, American Chamber of Commerce to the EU, American European Community Association (AECA), European Patients' Forum, EURORDIS, TRANSFORM Alliance, Alliance for Regenerative Medicines (ARM)

Organisation Members

See above

Additional Information

Bristol Myers Squibb Belgium has a corporate sponsorship with the Alliance of Liberals and Democrats for Europe for 2025. The amount of that corporate sponsorship is 18,000 euros and it is treated as a political donation. Bristol Myers Squibb Belgium has a cooperation agreement with The Wilfried Martens Centre for European Studies for 2025. The amount of that cooperation agreement is 12,000 euros and it is treated as a political donation In 2025 the number of BMS staff involved in covered activities increased as a result of the ongoing revision of the EU General Pharmaceutical Legislation and in light of the new mandate of the European Commission and the European Parliament.